News and Announcements
CannPal to present at the 2019 Asian Hemp Investment Summit
- Published June 26, 2019 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
KEY TAKEAWAYS:
- CannPal is presenting at the 2019 Asian Hemp Industry Investment Summit at the Kerry Hotel in Hong Kong on June 28th 2019
- Managing Director, Layton Mills, will be presenting on the Company’s progress and the opportunity for cannabinoids in the animal health market in Asia
- Mr Mills’s presentation is attached to this release.
Animal health company CannPal Animal Therapeutics Limited (ASX:CP1) (“CannPal” or “the Company”) is pleased to attach a presentation that will be delivered by CannPal Managing Director, Mr Layton Mills, at the 2019 Asian Hemp Industry Investment Summit at the Kerry Hotel in Hong Kong on June 28th 2019.
The purpose of the summit is to bring together cannabis industry leaders from all over the world, including expert groups on cannabis legislation in various countries, investment groups, and medical scientific research experts, to support the development of the Asian cannabis industry.
The forum is being co-hosted by the CBDG-Cannabis Industrial Fund alongside Arcview Group. The Arcview Investor Network includes more than 600 accredited investors who have put more than US$190 million behind 175 companies since inception.
About CannPal Animal Therapeutics
CannPal Animal Therapeutics Limited (ASX: CP1) is a pharmaceutical-focused animal health Company researching the benefits of medical cannabis for companion animals. CannPal is researching and developing medicines derived from cannabinoids to provide veterinarians with clinically validated and standardised therapeutics to treat animals in a safe and ethical way.
CannPal has identified a significant opportunity to benefit from the rapidly growing medical cannabis and health markets by developing innovate therapeutics derived from the cannabis plant. The Company is working closely with regulatory authorities and veterinary research organisations conducting clinical trials to commercialise therapeutic products that will meet regulatory approval and support the health and well-being of companion animals.
Company Updates
The Index Approach in Early-Stage Venture Capital: Reconsidered
The venture capital (VC) landscape is marked by its dynamism and complexity, especially in early-stage investing. The traditional approach in VC, characterised by a selective and intensive vetting process, often contrasts with the concept of ‘index investing.’ This article revisits the indexing approach in early-stage VC, incorporating insights from recent studies and data, including a […]
The Future Is Now: The Evolution of Dealflow with Wholesale Investor
If you’ve ever thought of investing or expanding your portfolio, there’s no better time than the present. In the fast-paced world of investment, things are changing at a breathtaking speed, and it’s crucial to stay ahead of the game. The Future of Deal Flow is Today Dealflow, the lifeblood of the investment world, is not […]
Investability of a Startup: A Comprehensive Guide for Angels and High-Net Worth Investors
Venturing into the Startup Scene Let’s dive into the intriguing world of startups. It’s a thrilling ride, isn’t it? Like finding a pearl in an ocean, spotting a promising startup amidst a sea of businesses is no easy task. This guide aims to light the way, focusing on the “The Investability of a Startup: 7 […]
Backed By Leading Investment Groups and Family Offices
